Nothing Special   »   [go: up one dir, main page]

WO2006061853A3 - Novel erythropoietic compounds and a process for producing erythropoietic compounds - Google Patents

Novel erythropoietic compounds and a process for producing erythropoietic compounds Download PDF

Info

Publication number
WO2006061853A3
WO2006061853A3 PCT/IN2005/000401 IN2005000401W WO2006061853A3 WO 2006061853 A3 WO2006061853 A3 WO 2006061853A3 IN 2005000401 W IN2005000401 W IN 2005000401W WO 2006061853 A3 WO2006061853 A3 WO 2006061853A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
erythropoietic
producing
erythropoietic compounds
novel
Prior art date
Application number
PCT/IN2005/000401
Other languages
French (fr)
Other versions
WO2006061853A2 (en
Inventor
Subhash V Kapre
Umesh S Shaligram
Original Assignee
Serum Inst India Ltd
Subhash V Kapre
Umesh S Shaligram
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst India Ltd, Subhash V Kapre, Umesh S Shaligram filed Critical Serum Inst India Ltd
Publication of WO2006061853A2 publication Critical patent/WO2006061853A2/en
Publication of WO2006061853A3 publication Critical patent/WO2006061853A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention is related to non-glycosylated EPO with improved stability and half lives. The present invention also provides a process for the preparation of a non-glycosylated EPO with improved stability and half life. The invention provides an erythropoietin compound comprising a non-glycosylated human erythropoietin and Y-PEG_NHS of the formula (I).
PCT/IN2005/000401 2004-12-10 2005-12-08 Novel erythropoietic compounds and a process for producing erythropoietic compounds WO2006061853A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN978MU2004 2004-12-10
IN978/MUM/2004 2004-12-10

Publications (2)

Publication Number Publication Date
WO2006061853A2 WO2006061853A2 (en) 2006-06-15
WO2006061853A3 true WO2006061853A3 (en) 2007-03-15

Family

ID=36578320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000401 WO2006061853A2 (en) 2004-12-10 2005-12-08 Novel erythropoietic compounds and a process for producing erythropoietic compounds

Country Status (1)

Country Link
WO (1) WO2006061853A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1848461A2 (en) * 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
CU20140003A7 (en) * 2014-01-08 2015-08-27 Ct De Inmunología Molecular Biofarmacuba CONJUGATE UNDERSTANDING ERYTHROPOYETIN AND A RAMIFIED POLYMER STRUCTURE

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002610A1 (en) * 1983-12-13 1985-06-20 Kirin-Amgen, Inc. Production of erythropoietin
WO2000032772A2 (en) * 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
WO2003055916A2 (en) * 2001-12-21 2003-07-10 Maxygen Aps Adiponectin fragments and conjugates
WO2004003176A2 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
WO2004019972A1 (en) * 2002-08-29 2004-03-11 F. Hoffmann-La Roche Ag Use of erythopoietin
WO2004022577A2 (en) * 2002-09-09 2004-03-18 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002610A1 (en) * 1983-12-13 1985-06-20 Kirin-Amgen, Inc. Production of erythropoietin
WO2000032772A2 (en) * 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
WO2003055916A2 (en) * 2001-12-21 2003-07-10 Maxygen Aps Adiponectin fragments and conjugates
WO2004003176A2 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
WO2004019972A1 (en) * 2002-08-29 2004-03-11 F. Hoffmann-La Roche Ag Use of erythopoietin
WO2004022577A2 (en) * 2002-09-09 2004-03-18 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin

Also Published As

Publication number Publication date
WO2006061853A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
HK1167658A1 (en) Composition for the preparation of 17-vinyl- triflates as intermediates 17--
CA2470183C (en) Intermediates for preparing arylsulphonamides and analogues
EA200401540A1 (en) SPYROINDOLINPIPERIDINE DERIVATIVES
JO2493B1 (en) Novel diphenylazetidione, Process for its preparation, medicaments comprising this compound and their use
EP2269694A3 (en) Antituberculous composition comprising oxazole compounds
EP1634874A4 (en) Imidazolidine derivative
PT1466947E (en) Azo compound
DE602006017038D1 (en) MENTHANCARBOXYL ACID AMID DERIVATIVES WITH COOLING CHARACTERISTICS
DE60233664D1 (en) PROCESS FOR THE PREPARATION OF PYRIDINE COMPOUNDS
WO2007038277A3 (en) Resolution of alpha-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines
IS6435A (en) Method for producing citalopram
WO2003011849A8 (en) Process for the production of beraprost and its salts
HUP0401600A2 (en) Process for the preparation of 14-hydroxymorphine derivatives
AU2003213422A1 (en) PROCESS FOR PRODUCING trans-4-AMINO-1-CYCLOHEXANECARBOXYLIC ACID DERIVATIVE
AU540658B2 (en) Cyclopropane derivatives
WO2006061853A3 (en) Novel erythropoietic compounds and a process for producing erythropoietic compounds
EP0312269A3 (en) 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as h3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents ypocholesterolemic agents
DE69931807D1 (en) PREPARATION OF ASCORBIC ACID USING YEAST
EP1535920A4 (en) Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
BR0109186A (en) Process for the preparation of spirocyclic tetronic acid derivatives
WO2002059089A3 (en) Process for the preparation of heterocyclic indene analogs
DK1347960T3 (en) Process for the preparation of (+/-) trans-4-p-fluorophenyl-3-hydromethyl-1-methylpiperidine
EP1698617A4 (en) Method for producing optically active cycloalkylidene bisoxazoline compound and intermediate thereof
DE69511449D1 (en) Octahydro-2-naphthalene carboxylic acid derivatives, their preparation and use
WO2003018572A1 (en) 3-(n-alkoxycarbonyl-n-methyl)amino-1-alkoxycarbonyl- oxy-(2-thienyl)propanes and process for preparing 3-(n- methylamino)-1-(2-thienyl)-propan-1-ol with the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05849152

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05849152

Country of ref document: EP

Kind code of ref document: A2